GPR183 and neurodegenerative disease: Modulation of the levels of CH25H, CYP7B1 and HSD3B7 enzymes directly in the brain may thus be another way to limit the increased chemotaxis or entry of EBI2-expressing encephalitogenic immune cells into the CNS during acute inflammation, neuroinflammatory disease or neurodegenerative diseases.